Sam Brown Inc.
July 18, 2011
Yaupon Therapeutics, Inc. Appoints New
New management to focus on NDA submission for proprietary
gel formulation of mechlorethamine hydrochloride to treat early
stage (stages I-IIA) mycosis fungoides, a type of Cutaneous
MALVERN, PA (July 18, 2011) – Yaupon
Therapeutics, Inc., a privately held specialty pharmaceutical
company, announced today the appointment of nine new management
team members. The new management team will strengthen the
company’s foundation and drive momentum as it prepares the NDA
submission for its proprietary gel formulation of mechlorethamine
hydrochloride for the treatment of early stage (stages I-IIA)
mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL).
Steve Tullman, Yaupon Chairman and CEO, was
recently chosen to lead the company during this pivotal time.
Mr. Tullman has a proven track record in the industry and is
known for his ability to advance biotechnology companies while
building value for shareholders. Mr. Tullman also serves as the
Chairman of Vicept Therapeutics, Inc. and was most recently the
co-founder, President and CEO of Ception Therapeutics, Inc.
which was acquired by Cephalon, Inc. in April 2010. The majority
of the new management team, detailed below, served in leadership
positions with Mr. Tullman at Ception.
Tim Henkel, M.D., Ph.D., Appointed
Executive Vice President, Head of Research and Development,
Yaupon. Previously, Dr. Henkel served as the Executive Vice
President of Research and Development at Ception Therapeutics,
as Chief Medical Officer of Vicuron Pharmaceuticals (acquired by
Pfizer) and as a Vice President at GlaxoSmithKline.
Doug Gessl Appointed Chief Operating
Officer and Chief Financial Officer, Yaupon. Previously, Mr.
Gessl was Chief Financial Officer of Ception Therapeutics, and a
Senior Vice President with Einhorn Associates. He acted as
financial advisor and lead negotiator for Fulcrum
Pharmaceuticals, Inc., a legacy company to Ception.
H. Jeffrey Wilkins, M.D., Appointed Chief
Medical Officer, Yaupon. Prior to joining Yaupon
Therapeutics, Dr. Wilkins served as Vice President of Worldwide
Clinical Development: Oncology and Immunology of Cephalon and
Senior Vice President of Clinical Development of Ception
Therapeutics. He entered the pharmaceutical industry joining
GlaxoSmithKline after ten years as a family medicine physician
and CEO of a large multi-center group, TriValley Primary Care.
Rounding out the new management team:
Evan Dick, Ph.D., Senior Vice President of
Kelly Copeland, Vice President of Product
Jim Dowell, Ph.D., Vice President of
Jeffrey Shaver, Ph.D., Vice President of
Project Management and Operations
Martin Stogniew, Ph.D., Vice President of
Lisa Wittmer, Ph.D., Vice President of
“We are focused on the preparation of the NDA
submission for Yaupon’s first product. To complete this
important task we gathered a highly experienced management team
who work well together and deliver accurate results quickly,”
said Yaupon Chairman and CEO Steve Tullman. “This team brings
together diverse and proven clinical, regulatory and
commercialization expertise that will help drive Yaupon to the
About Yaupon Therapeutics
Yaupon Therapeutics, a privately held, specialty
pharmaceutical company, is developing a proprietary gel
formulation of mechlorethamine hydrochloride for the treatment
of early stage (stages I-IIA) mycosis fungoides, a type of
Cutaneous T-Cell Lymphoma (CTCL). Based upon results of a
recently completed trial, Yaupon intends to file a new drug
application (NDA) with the Food and Drug Administration (FDA) in
2011. If approved, Yaupon’s investigational drug would be the
first topical mechlorethamine gel widely available to relieve
the signs and symptoms of this rare cancer. Please visit the new
www.yaupontherapeutics.com for more information.
# # #
Sam Brown Inc.
Mike Beyer, 773-463-4211